China’s NRDL continues to evolve at pace and 2025 marked one of the most competitive cycles to date. At the same time, the C-list is emerging as an alternative pathway, bringing new strategic trade-offs for manufacturers. With updated pharmacoeconomic evaluation guidelines and the introduction of comparator pre-communication pilots, the NRDL landscape is becoming even more dynamic.
In this webinar recording, our experts break down the latest developments and what they mean for NRDL 2026 and beyond.
Watch this session to explore:
- Key trends from the latest NRDL cycle and what to expect for 2026
- Implications of new policies and pharmacoeconomic guidelines
- Critical success factors and practical takeaways for future submissions
Gain the insights you need to navigate increasing competition and position your strategy for success in the upcoming NRDL cycle.
